



GEDEON RICHTER

## **Richter announces the closing of the acquisition of Janssen's Evra® transdermal contraceptive patch assets**

**Budapest, Hungary – 7 January 2021** – Gedeon Richter Plc. ("Richter") announced on 3 December 2020 that it signed an asset purchase agreement with Janssen Pharmaceutica NV ("Janssen"), a wholly owned subsidiary of Johnson & Johnson, in respect of Janssen's Outside US Evra® transdermal contraceptive patch assets.

The conditions of the closing were met, consequently the transaction was closed.

### **About Richter**

Gedeon Richter Plc. ([www.richter.hu](http://www.richter.hu)), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalization of EUR 3.6 billion (USD 4.1 billion) by the end of 2019, Richter's consolidated sales were approximately EUR 1.6 billion (USD 1.7 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

### **For more information:**

#### **Investors:**

Katalin Ördög: +36 1 431 5680

#### **Media:**

Zsuzsa Beke: +36 1 431 4888

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary  
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944  
EU Community VAT Identification No: HU 10484878 • Internet: [www.richter.hu](http://www.richter.hu)